Compare BioNano Genomics Inc (BNGO) vs Charter Communications Inc (CHTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Charter Communications Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Charter Communications Inc trades at $150.33 (market cap $18.81B). The key difference: Charter Communications Inc is far larger — about 1377× BioNano Genomics Inc's market cap, and Charter Communications Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CHTR | |
|---|---|---|
Market Cap | $13.66M | $18.81B |
Sector | Health | Media |
52-Week High | $4.92 | $282.74 |
52-Week Low | $1.06 | $123.31 |
Enterprise Value | $16.26M | $115.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Charter Communications (CHTR) trades at $153.29, up 0.47% today, near its pivot point of $152. The stock shows mixed technical signals with a bullish moving average trend but bearish oscillators. Fundamentally, it trades at low valuation multiples (P/E 4.1, P/S 0.37) with solid profitability (ROE 29.7%, net margin 9.05%), though Q1 2026 earnings missed expectations. Recent news highlights debt refinancing activities and competitive pressures in broadband.
Outlook: CHTR presents a value opportunity with deep discount to historical multiples, supported by strong cash flow and buybacks, but faces headwinds from subscriber losses and high debt load. Risks include fiber competition and revenue declines, while analyst consensus leans bullish with a $166.18 price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
